In this study, we examined a large number of patients to clarify FLT3 gene has some structural similarities including the the distribution and frequency of a recently described FLT3 tannumber of exons, size of exons and exon/intron boundaries dem duplication among hematopoietic malignancies, including with genes RTKs, FMS, KIT, and platelet-derived growth-factor reported.
Introduction

Materials and methods
The FLT3 (fms-like tyrosine kinase, also named FLK2 or STK1)
Patients and samples gene encodes a receptor tyrosine kinase (RTK) that is closely related to two well-known receptors, KIT and FMS, that reguThis study included 112 adult de novo AML, 37 MDS, 55 late proliferation and differentiation of hematopoietic cells adult ALL, 14 adult T cell leukemia (ATL), 30 non-Hodgkin's with their respective ligands, stem-cell factor (SCF) and lymphoma (NHL), 15 chronic lymphocytic leukemia (CLL), 38 macrophage colony-stimulating factor (M-CSF). [1] [2] [3] [4] Initial studmultiple myeloma (MM), seven chronic myelogenous leukeies have reported that FLT3 is expressed in the hematopoietic mia (CML) in chronic phase (CP), 13 CML in blastic phase and nervous system, the gonads and the placenta. 3, 5 Since (BC), and three essential thrombocythemia (ET). All AML and FLT3 is expressed predominantly in primitive hematopoietic ALL patients were examined at presentation. The diagnoses of cells showing CD34 molecules, it might regulate the early patients with AML and MDS were made according to the events of hematopoietic development. 2, 4 In hematological French-American-British (FAB) classification (Table 1) .
NHL including six Burkitt's cell lymphoma (BL), and two MM. in any case, as we reported previously. 14 Two patients, L184 and L319, showed abnormal bands only after amplification  The names and origin of cell lines were as follows: AMLderived cell lines, MOLM-13, M-07e, HL-60, PL-21, KG-1, by a 11F/12R primer combination. All 23 patients were restricted only to AML and MDS. In the patients with other hematol-ML-1, ML-2, MKB-1, THP-1-0, EoL-1, and ME -1; ALL-derived  cell lines, NALM-19, NALM-26, NALM-30, NALM-27,  ogical malignancies, including ALL, ATL, NHL, CLL, MM,  CML, and ET, no length abnormalities were detected.  NALM-28, NALM-21, NALM-31, NALM-32, BV-173, HAL-1,  OM9;22, NALM-29, NALM-24, NALM-33, KOPN-8, NALM inated from AML-M5, had a length abnormality ( Table 1 ). The other cell lines derived from either ALL, AUL, HCL, CML, ML those derived from BL, BALM-13, BALM-14, BALM-9, BALM-10, BALM-11, and BALM-12; those derived from MM, RPMIor MM showed no abnormality, demonstrating again the restriction of this abnormality to AML. Interestingly, the inci-8226, and ARH-77. Cells were grown and maintained by serial passages in appropriate media supplemented with 10-20% dence of FLT3 abnormality in AML cell lines (1/11, 9%) was not higher than that of the patient's (20%). (v/v) heat-inactivated fetal bovine serum (PBS).
PCR amplification of exon 11 to exon 19 of the FLT3 gene showed no products of unusual size (data not shown), suggesting the length mutation was restricted to exons 11 and 12 in Screening of the length mutation in TM, JM, and kinase domains of FLT3 gene by genomic PCR the FLT3 gene.
Genomic DNA was extracted from bone marrow samples using a standard procedure. 17 To detect the length mutation
Most of the length abnormalities in JM and 5′ TK-I domains of FLT3 gene were originated from internal in the JM and 5′ TK-I domains by PCR method, we used two sets of primers, 10F/10R and 11F/11R, as described in the pretandem duplication vious study. 14 The former set of primers covers the whole exon 10 which encodes the entire TM domain and the first 19 We sequenced the PCR products the length of which were larger than the wild-type in 22 AML and one MDS patient and nucleotides of the JM domain. The latter set of primers amplifies the whole exon 11 encoding a remaining JM and the one cell line, MOLM-13. We also deduced the amino acid sequences from the DNA sequences. In 23 of 24 cases examinitial 16 nucleotides of the TK-I domains.
14 The products were electrophoresed on 2% agarose gel (FMC, Rockland, ined, the tandem duplication in exon 11 was observed. In one AML patient, L429, insertion of 36 nucleotides and deletion ME, USA) and 8% polyacrylamide gel. When an unexpected product was obtained, it was confirmed by a repeated PCR.
of three nucleotides without duplication within exon 11 was determined. We summarized the characteristics of 24 Since duplication may involve the intron sequence between exons 11 and 12 like case M155 in the previous study, amplisequences in the present study (Table 2, Figure 1 ). The length of duplicated DNA sequences varied from 17 to fication of exons 11 to 12 using the 11F/12R primer combination, based on the genomic sequence of the FLT3 gene, was 198 bp. Most markedly, the starting and ending sites of duplication were different in each case; therefore, no identical also carried out to confirm the length abnormality.
11 In order to analyze the intracellular region of the FLT3 receptor, we duplication was observed. However, the target regions for duplication seemed to be limited. In 21 of 23 cases with the also analyzed exon 12 to 19 by genomic amplification. 14 tandem duplication, the target sequences of duplication were restricted within exon 11. However, one case, L319, included the initial 4-bp intron sequence and another case, L184, Sequencing including a whole intron and a 5′ part of exon 12. In the former case, the duplicated part of the intron sequence seemed Abnormal PCR fragments were cloned into pCRII plasmid vector (Invitrogen, San Diego, CA, USA) and sequencing was carto be involved in the reading frame. In the latter case, a new exon was presumably created by tandem fusion of a 5′ part ried out using a T7 sequencing kit (Pharmacia LKB, Uppsala, Sweden). Alternatively, a DNA sequencing system (Model of exon 12 and a 3′ part of exon 11 like case M155 in our previous study where we confirmed this configuration by 373A; Applied Biosystems, Foster City, CA, USA) was used to sequence cloned fragments.
RT-PCR.
14 In 15 cases, simple duplication occurred without any deletion or insertion of nucleotides within exon 11. The numbers of nucleotides duplicated in all these cases were mulResults tiples of three. In five (L231, L305, L453, L267, and MOLM-13) of these cases, the duplication was initiated at the first Length mutations in JM and 5′ TK-I domains of FLT3 gene were completely restricted to AML and MDS nucleotide of each coding triplet, which could make the altered transcripts strictly in-frame. In the remaining 10 cases, three (L335, L324 and L332) had only a substitution of the Among 324 patients with hematological malignancies examined by the amplification of genomic DNA, 23 had longer first position of the added AA sequence by the other AA (E to D), and seven coincidentally had the same AA sequences PCR products by amplifying exons 11 and 12 of the FLT3 gene ( Table 1 ). The length abnormality was not found in exon 10 despite the nucleotide sequence in the junctional codon being 
Diagnosis
No. of cases Length mutation in examined JM and 5′TK-I of
Discussion
FLT3 gene (%)
In the present study of a large number of hematological malig-AML (total) 112 22 (20) nancies, we found that the length mutation was restricted to by amplification of genomic DNA either in CP or BC. This domains. All of the abnormal products were in-frame and the
deduced AA sequence of TK-I domain remained unchanged.
RAEB-T 9 1 (11)
In addition, we found the minimum AA regions in the JM
domain that were inevitably involved in the duplication. The expression of FLT3 mRNA was seen in the majority of was not detected in other hematological neoplasms. Recent
studies revealed that FLT3 ligand led to a significant proliferat-
ive response in leukemic cells from either fresh samples or
cultured cells of AML. 20 In contrast, the leukemic cells from precursor-B-ALL did not respond well to FL even in the cases can only occur in myeloid lineage. Acquisition of FLT3 mutation might not influence the growth of leukemic cells in the majority of ALL cases. The finding that the length mutation was not detected in a large number of ALL-derived cell lines seem to support this hypothesis. altered. In eight of 23 cases who had the tandem duplication, insertion of nucleotides, ranging from two to 22, was observed
The fact that all the tandem duplications resulted in inframe strongly suggest that the abnormal protein product between the duplicated regions. Accordingly, the numbers of nucleotides added to the wild-type by duplication and inserderived from this mutation functions dominantly and increases the growth of the leukemic cell. tion varied from 18 to 204. Interestingly, the insertion of these nucleotides made the total number of increased nucleotides
The mechanisms by which the length mutation affect cell growth is of great interest. We have shown that an insertional multiples of three. In most cases where the numbers of duplicated sequences were multiples of three, no insertion of mutation was not detected in the extracellular part of FLT3.
14 The recent study on the kinase activity of EGF receptor by nucleotides occurred. In three cases, L179, L428, and L319, the inserted nucleotides could be assigned to nt 1-12 of intron introducing insertional mutations revealed that insertion of hydrophilic AA sequences on both the extracellular and cyto-11, nt 1744-1765, and nt 1785-1793 of exon 11, respectively. In six of nine cases, inserted sequences could not be plasmic sides of the TM domain exhibited dramatically reduced EGF binding but enhanced kinase activity. In conmatched to any part of the wild-type sequences of whole cDNA and intron 11 of FLT3.
trast, insertion of AA sequence in the juxtamembrane domain of the cytoplasmic side alone affected neither the EGF-binding By comparing the abnormal sequences with wild-type TM, JM, and TK-I sequences, we determined the extents of the ability nor the kinase activity of the EGF receptor. 23 Therefore, elongation of the intracellular JM domain alone might not duplicated regions (Table 2, Figure 1) . In any case, the deduced AA sequence at the end of the JM domain remained enhance the cell growth. Another possible mechanism is a gain of a specific AA unchanged. Most interestingly, there was no duplication that started downstream of nt 1882, the starting point of the coding sequence which binds with SH2-containing cytoplasmic signalling proteins. SH2 domains directly recognize certain phosregion for TK-I. This means that the continuity of a wild-type coding sequence of TK-1 remains intact by this mutation in phorylated tyrosine residues of the RTK protein. It has been elucidated that the SH2-binding autophosphorylation residues ␤PDGF receptor, we found a homologous motif, YFYV (AA number 589-592 in Ref. 4) , at the same location of the JM are clustered within non-catalytic regions of the cytoplasmic domains of the EGF receptor and PDGF receptor. 24 In the JM domain of FLT3. Interestingly, this motif was doubled in 12 of 23 cases with the tandem duplication ( Figure 1 ). Another domain of ␤PDGF receptor, Y579 and Y581 are implicated in binding to c-Src, a cytoplasmic tyrosine kinase. 25 These tyro-AA sequence, YEYDLK (AA number 597-602 in Ref. 4 ) which contains either YEYD or YDLK, was frequently involved in the sine residues were auto-phosphorylated and composed a SH2-binding motif, YIYV. In comparison with the JM sequence of duplicated AA sequences. YEYDLK was seen in 11 cases,
